Researchers are optimistic after early results showed that experimental drug treatment zorevunersen may significantly reduce the number of seizures in children with a rare and severe form of epilepsy.
The trial, led by University College London and Great Ormond Street Hospital, involved 81 children aged two to 18 with Dravet syndrome – a rare genetic disorder that begins with seizures in the first year of life and evolves into treatment-resistant epilepsy – in the UK and US.
